Cargando…

Malignancy in Systemic Lupus Erythematosus (SLE) Patients

BACKGROUND: Malignancies are among the leading causes of death in Systemic Lupus Erythematosus (SLE) patients with studies reporting a higher prevalence of malignancy in SLE patients compared to the general population. We wanted to determine the frequency of cancer in a cohort of SLE patients and id...

Descripción completa

Detalles Bibliográficos
Autores principales: Cader, Rizna Abdul, Yee, Amy Khoo Mei, Yassin, Azrul, Ahmad, Ismail, Haron, Siti Nurfatin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428534/
https://www.ncbi.nlm.nih.gov/pubmed/30583682
http://dx.doi.org/10.31557/APJCP.2018.19.12.3551
_version_ 1783405412509286400
author Cader, Rizna Abdul
Yee, Amy Khoo Mei
Yassin, Azrul
Ahmad, Ismail
Haron, Siti Nurfatin
author_facet Cader, Rizna Abdul
Yee, Amy Khoo Mei
Yassin, Azrul
Ahmad, Ismail
Haron, Siti Nurfatin
author_sort Cader, Rizna Abdul
collection PubMed
description BACKGROUND: Malignancies are among the leading causes of death in Systemic Lupus Erythematosus (SLE) patients with studies reporting a higher prevalence of malignancy in SLE patients compared to the general population. We wanted to determine the frequency of cancer in a cohort of SLE patients and identify its associated risk factors. METHODS: Cross-sectional study involving SLE patients attending the nephrology outpatient clinic, Universiti Kebangsaan Malaysia Medical Centre between January and June 2014. RESULTS: We recruited 228 patients (207 female, 21 male), aged 40.48 ± 12.86 years with mean SLE duration of 11.65 ± 6.46 years. Majority (87%) had lupus nephritis and were in remission with a median SLEDAI score 2 (0, 14). Majority (89%) were on corticosteroid with either a steroid sparing agent like mycophenolate mofetil (15.4%), azathioprine (36.8%) or ciclosporin (15.4%). One hundred and sixty (70.2%) patients were either receiving or had received intravenous cyclophosphamide with median dose of 5,173.6 ± 3,242.4 mg. Seven female patients were diagnosed with cancer during the course of their SLE with 56 (34-78) years being median age at malignancy and SLE duration of 4 (0-12) years. Majority (5/7) had lupus nephritis and all patients a median dose of prednisolone 10 (2.5, 10) mg with 10 (4-24) years of steroids. Two patients had a family history of cancer with majority developing cancer after the diagnosis of SLE. Two patients received intravenous cyclophosphamide prior to the development of cancer for their SLE compared to overall cohort of 160. Three patients had colorectal cancer, 2 had cervical cancer, 1 had breast cancer, and one patient had germ cell tumour and one thyroid cancer. All patients had their cancer successful treated with no signs of recurrence. CONCLUSION: We found a lower occurrence of cancer in our SLE patients as compared with the reported literature.
format Online
Article
Text
id pubmed-6428534
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-64285342019-04-01 Malignancy in Systemic Lupus Erythematosus (SLE) Patients Cader, Rizna Abdul Yee, Amy Khoo Mei Yassin, Azrul Ahmad, Ismail Haron, Siti Nurfatin Asian Pac J Cancer Prev Research Article BACKGROUND: Malignancies are among the leading causes of death in Systemic Lupus Erythematosus (SLE) patients with studies reporting a higher prevalence of malignancy in SLE patients compared to the general population. We wanted to determine the frequency of cancer in a cohort of SLE patients and identify its associated risk factors. METHODS: Cross-sectional study involving SLE patients attending the nephrology outpatient clinic, Universiti Kebangsaan Malaysia Medical Centre between January and June 2014. RESULTS: We recruited 228 patients (207 female, 21 male), aged 40.48 ± 12.86 years with mean SLE duration of 11.65 ± 6.46 years. Majority (87%) had lupus nephritis and were in remission with a median SLEDAI score 2 (0, 14). Majority (89%) were on corticosteroid with either a steroid sparing agent like mycophenolate mofetil (15.4%), azathioprine (36.8%) or ciclosporin (15.4%). One hundred and sixty (70.2%) patients were either receiving or had received intravenous cyclophosphamide with median dose of 5,173.6 ± 3,242.4 mg. Seven female patients were diagnosed with cancer during the course of their SLE with 56 (34-78) years being median age at malignancy and SLE duration of 4 (0-12) years. Majority (5/7) had lupus nephritis and all patients a median dose of prednisolone 10 (2.5, 10) mg with 10 (4-24) years of steroids. Two patients had a family history of cancer with majority developing cancer after the diagnosis of SLE. Two patients received intravenous cyclophosphamide prior to the development of cancer for their SLE compared to overall cohort of 160. Three patients had colorectal cancer, 2 had cervical cancer, 1 had breast cancer, and one patient had germ cell tumour and one thyroid cancer. All patients had their cancer successful treated with no signs of recurrence. CONCLUSION: We found a lower occurrence of cancer in our SLE patients as compared with the reported literature. West Asia Organization for Cancer Prevention 2018 /pmc/articles/PMC6428534/ /pubmed/30583682 http://dx.doi.org/10.31557/APJCP.2018.19.12.3551 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Cader, Rizna Abdul
Yee, Amy Khoo Mei
Yassin, Azrul
Ahmad, Ismail
Haron, Siti Nurfatin
Malignancy in Systemic Lupus Erythematosus (SLE) Patients
title Malignancy in Systemic Lupus Erythematosus (SLE) Patients
title_full Malignancy in Systemic Lupus Erythematosus (SLE) Patients
title_fullStr Malignancy in Systemic Lupus Erythematosus (SLE) Patients
title_full_unstemmed Malignancy in Systemic Lupus Erythematosus (SLE) Patients
title_short Malignancy in Systemic Lupus Erythematosus (SLE) Patients
title_sort malignancy in systemic lupus erythematosus (sle) patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428534/
https://www.ncbi.nlm.nih.gov/pubmed/30583682
http://dx.doi.org/10.31557/APJCP.2018.19.12.3551
work_keys_str_mv AT caderriznaabdul malignancyinsystemiclupuserythematosusslepatients
AT yeeamykhoomei malignancyinsystemiclupuserythematosusslepatients
AT yassinazrul malignancyinsystemiclupuserythematosusslepatients
AT ahmadismail malignancyinsystemiclupuserythematosusslepatients
AT haronsitinurfatin malignancyinsystemiclupuserythematosusslepatients